India, May 1 -- MapLight Therapeutics, Inc. (MPLT) said it has completed enrolment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for schizophrenia, marking a key milestone as the company advances two mid-stage programs toward data readouts this summer.
The company also completed the final patient visit in its Phase 2 IRIS trial of ML-004 for autism spectrum disorder.
Schizophrenia is a chronic psychiatric disorder characterized by hallucinations, delusions, and cognitive impairment, often requiring long-term treatment. ML-007C-MA is designed to modulate neural circuits involved in psychosis, and the ZEPHYR study enrolled 307 adults experiencing an acute exacerbation of symptoms. Participants were randomized to receive placebo or one o...